|
|
c-Met inhibitor JNJ-38877605 An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met (mesenchymal-epithelial transition), a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis.
c-Met is also known as hepatocyte growth factor receptor (HGFR). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Code name: | | JNJ-38877605 | | |
|
|